It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The impact of pesticides on health is a major public health concern. A higher risk to develop chronic lymphoid malignancies has been demonstrated to be associated with occupational pesticide exposure (OPE). By contrast, little is known of the impact of OPE on the occurrence of myeloid malignancies especially acute myeloid leukemia (AML). The purpose of this meta-analysis is to summarize data on the association between OPE and AML. A relevant dataset of case–control studies was extracted. Among 6784 references extracted, 14 were selected, representing 3,955 AML patients and 9,948 control subjects diagnosed between 1976 and 2010. An adverse association was found between OPE and AML (OR = 1.51; 95%CI: 1.10–2.08), not affected by sensitivity analyses. Funnel plot asymmetry suggested a publication bias underestimating OR. Stratified analysis showed the association to be driven by studies with: (1) monocentric AML patients and hospital-based control population, (2) Newcastle–Ottawa scale > 6 and the group of studies identified as with the lowest risk, (3) exposure assessment through peer-to-peer interview, (4) diagnosis in North America and Asia and after 1995, (5) restriction to de novo AML. Moreover, the association between OPE and AML was significant with insecticides. These findings broaden the spectrum of pesticide toxicity to myeloid malignancies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tours University Hospital, Department of Biological Hematology, Tours, France (GRID:grid.411167.4) (ISNI:0000 0004 1765 1600); Tours University, CNRS ERL7001 LNOX, EA 7501, Tours, France (GRID:grid.12366.30) (ISNI:0000 0001 2182 6141)
2 Tours University Hospital, Department of Hematology and Cell Therapy, Tours, France (GRID:grid.411167.4) (ISNI:0000 0004 1765 1600)
3 Nantes University Hospital, Department of Biological Hematology, Nantes, France (GRID:grid.277151.7) (ISNI:0000 0004 0472 0371)
4 Tours University, CNRS ERL7001 LNOX, EA 7501, Tours, France (GRID:grid.12366.30) (ISNI:0000 0001 2182 6141); Tours University Hospital, Department of Hematology and Cell Therapy, Tours, France (GRID:grid.411167.4) (ISNI:0000 0004 1765 1600)